Table 1.

Baseline demographics and clinical characteristicsa

CharacteristicSafety Population(n = 72)Assessment Phase Population(n = 53)
Gender (n [%])
    male45 (63)33 (62)
    female27 (38)20 (38)
Race (n [%])
    black38 (53)25 (47)
    white30 (42)25 (47)
    other4 (6)3 (6)
Age (yr [mean ± SD])56.9 ± 11.857.8 ± 12.8
Active vitamin D derivative use (n [%])72 (100)53 (100)
Phosphate binder use (n [%])71 (99)53 (100)
biPTH (pg/ml [mean ± SD])118.9 ± 32.5\f117.3 ± 32.0\f
Ca × P (mg2/dl2 [mean ± SD])59.6 ± 14.663.8 ± 10.8
Serum calcium (mg/dl [mean ± SD])9.7 ± 0.79.7 ± 0.7
Serum phosphorus (mg/dl [mean ± SD])6.2 ± 1.56.6 ± 1.2
  • a biPTH, biointact parathyroid hormone; Ca × P, calcium-phosphorus product. Dialysate calcium concentration 2.5 mEq/L was used.\